Cargando…
M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
BACKGROUND: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity. SEP-363856 showed significant antipsychotic efficacy in patients with schizophrenia, and a safety and tolerability profile similar to placebo and consistent with...
Autores principales: | Milanovic, Snezana, Origala, Ajay, Dworak, Heather, Hopkins, Seth, Koblan, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234762/ http://dx.doi.org/10.1093/schbul/sbaa030.520 |
Ejemplares similares
-
Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021) -
Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021) -
Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
por: Liang, Lingzhi, et al.
Publicado: (2022) -
T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018) -
Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
por: Begni, Veronica, et al.
Publicado: (2021)